172 related articles for article (PubMed ID: 36067528)
1. Acute generalized pustular psoriasis successfully treated with the IL-23p19 antibody risankizumab.
Heyer S; Seiringer P; Eyerich S; Pilz AC; Steimle-Grauer SA; Eyerich K; Biedermann T; Böhner A
J Dtsch Dermatol Ges; 2022 Oct; 20(10):1362-1364. PubMed ID: 36067528
[No Abstract] [Full Text] [Related]
2. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
McDonald J; Maliyar K; Gooderham MJ
Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
[TBL] [Abstract][Full Text] [Related]
3. Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
Paton DM
Drugs Today (Barc); 2019 Oct; 55(10):605-613. PubMed ID: 31720558
[TBL] [Abstract][Full Text] [Related]
4. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
[TBL] [Abstract][Full Text] [Related]
5. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
6. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
7. Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L; Maloney V; Gordon KB
Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
[TBL] [Abstract][Full Text] [Related]
8. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
Xu S; Zhang X; Pan M; Shuai Z; Xu S; Pan F
Int Immunopharmacol; 2019 Oct; 75():105841. PubMed ID: 31465912
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab-induced paradoxical pustular psoriasis.
McFeely O; Pender E; Victory L; Almutlaq H; Storan E
Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
[TBL] [Abstract][Full Text] [Related]
10. Risankizumab: First Global Approval.
McKeage K; Duggan S
Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
[TBL] [Abstract][Full Text] [Related]
11. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab.
Pavia G; Gargiulo L; Spinelli F; Avagliano J; Valenti M; Borroni RG; Costanzo A; Narcisi A
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e502-e505. PubMed ID: 35224780
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
[TBL] [Abstract][Full Text] [Related]
14. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
[TBL] [Abstract][Full Text] [Related]
15. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ; Warren RB; Cather JC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
[TBL] [Abstract][Full Text] [Related]
16. Update on risankizumab for the treatment of moderate to severe psoriasis.
Al-Janabi A; Warren RB
Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
[TBL] [Abstract][Full Text] [Related]
17. Review of treatments for generalized pustular psoriasis.
Kearns DG; Chat VS; Zang PD; Han G; Wu JJ
J Dermatolog Treat; 2021 Aug; 32(5):492-494. PubMed ID: 31697211
[TBL] [Abstract][Full Text] [Related]
18. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).
Schmick K; Grabbe J
Br J Dermatol; 2004 Feb; 150(2):367. PubMed ID: 14996114
[No Abstract] [Full Text] [Related]
19. Tildrakizumab for the treatment of psoriasis.
Bangert C; Kopp T
Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
[TBL] [Abstract][Full Text] [Related]
20. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
[Next] [New Search]